Nicotine Lozenges

DRUG4 trials

Sponsors

Mayo Clinic, GlaxoSmithKline, Wake Forest University Health Sciences

Conditions

Bipolar DisorderMental IllnessPersistent Depressive DisorderRecurring Major Depressive DisorderSchizoaffective DisorderSchizophreniaSmokeless Tobacco UseTobacco Dependence

Phase 1

First Time in Human Study With GSK1018921

CompletedNCT00527020

GlaxoSmithKlineSchizophrenia

Start: 2007-08-10End: 2008-07-12Updated: 2017-08-04

Phase 2

Nicotine Lozenge or Tobacco-Free Snuff for Smokeless Tobacco Reduction

CompletedNCT01018394

Mayo ClinicTobacco Dependence

Start: 2009-01-31End: 2012-07-31Updated: 2013-09-13

Phase 3

Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction

CompletedNCT00392379

Mayo ClinicSmokeless Tobacco Use

Start: 2007-01-31End: 2009-03-31Updated: 2013-04-24

Unknown Phase

Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings

CompletedNCT05030272

Wake Forest University Health SciencesBipolar Disorder, Mental Illness, Persistent Depressive Disorder +4

Start: 2021-09-21End: 2025-12-30Updated: 2026-02-27